FOLH1 and neoplasm: The enhanced therapeutic effects of 161Tbcompared to 177Lu became obvious from in-vitro data wherethe exposure to 161Tb-PSMA-617 reduced the viability andsurvival of PC-3 PIP tumor cells in an activity-dependent manner.